CBM Cambrex Corp

Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that it has completed the acquisition of PharmaCore, Inc., a privately-owned company located in High Point, North Carolina, specializing in developing, manufacturing and scaling up small molecule APIs for clinical phase projects.  This completes the transaction initially announced on September 26, 2016.  With the acquisition of PharmaCore, which has been renamed Cambrex High Point, Inc., Cambrex enhances its capabilities and expertise to efficiently develop early clinical phase products and new technologies. 

Forward Looking StatementsThis document contains "forward-looking statements," including statements regarding expected impact of the PharmaCore acquisition on earnings per share and other potential benefits of the transaction.  These and other forward looking statements may be identified by the fact that they use words such as "expects," "anticipates," "intends," "estimates," "believes" or similar expressions.  Any forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations.  The factors described in Item 1A of Part I of the Company's Annual Report on Form 10-K for the period ended December 31, 2015, captioned "Risk Factors," or otherwise described in the Company's filings with the SEC provide examples of such risks and uncertainties that may cause the Company's actual results to differ materially from the expectations the Company describes in its forward-looking statements. Important factors include, but are not limited to, the risk that the expected benefits of the transactions may not be realized to the extent we anticipate or at all, unexpected delays in the completion of ongoing capital projects, pharmaceutical outsourcing trends, competitive pricing or product developments, market acceptance and adoption rate of our customers' products, government legislation and regulations (including those pertaining to environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation, environmental matters, changes in foreign exchange rates, uncollectible receivables, the timing of orders or shipments and the Company's ability to meet its production plan and customer delivery schedules, expected timing of completion of capacity expansions, loss on disposition of assets, cancellations or delays in renewal of contracts, lack of suitable raw materials, the Company's ability to receive regulatory approvals for its products, continued demand in the U.S. for late stage clinical products and the successful outcome of the Company's investment in new products.

For further details and a discussion of these and other risks and uncertainties, investors are encouraged to review the Cambrex Annual Report on Form 10-K for the fiscal year ended December 31, 2015, including the Forward-Looking Statement sections therein, and other filings with the SEC.  The Company cautions investors and potential investors not to place significant reliance on the forward-looking statements contained in this press release and to give careful consideration to the risks and uncertainties listed above and contained in our SEC filings. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements.

About CambrexCambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics.  The Company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances.  For more information, please visit www.cambrex.com.

Contact: 
Alex Maw
Director, Marketing and Communications
Tel: +44 7803 443 155
Email: alex.maw@cambrex.com